Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. - Wikidata - awgldk - TriplyDB

Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.

Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.

http://www.wikidata.org/entity/Q35800752

about

Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results.Experimental approaches for the treatment of malignant gliomas.Cerebral blood volume calculated by dynamic susceptibility contrast-enhanced perfusion MR imaging: preliminary correlation study with glioblastoma genetic profiles.Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure.Cytotoxic and molecular chemotherapy for high-grade glioma: an emerging strategy for the future.Chemotherapy in the treatment of malignant gliomas.Topoisomerase I inhibitors for the treatment of brain tumors.Experience with irinotecan for the treatment of malignant glioma An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting.Evidence and Context of Use for Contrast Enhancement as a Surrogate of Disease Burden and Treatment Response in Malignant Glioma.

P2860

Q33382342-8EE86722-34D3-48D2-82A8-6B80B55FCFBE Q34127138-BA18D973-D713-443F-9B73-9C93374A919E Q34971940-F2DC7ECC-27FB-4B55-97B0-2E9E10E819B9 Q35800735-50B0EE77-DBE3-4EDE-81AD-FD70B724D24F Q36113188-A9652EE8-6C18-4EA8-9550-CD1417EF76B0 Q36429731-50357131-101A-48EB-A2A0-BB77161F1691 Q36499238-35EABA66-4DAB-4F91-A1FB-AD5D111E158A Q37159504-779E7D1A-E4CF-4BD5-AE13-43F5CF25F0CB Q37265907-246DC696-5302-4080-B723-1D0EB7244A9C Q37858468-9130C745-06FF-4567-8273-ECC2E17DB807 Q47436703-03A441D9-3E99-48CF-96F8-0A3355B39004

P2860

Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.

http://www.wikidata.org/entity/Q35800752

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Phase 1 trial of irinotecan pl ...... or recurrent malignant glioma.

@ast

Phase 1 trial of irinotecan pl ...... or recurrent malignant glioma.

@en

type

label

Phase 1 trial of irinotecan pl ...... or recurrent malignant glioma.

@ast

Phase 1 trial of irinotecan pl ...... or recurrent malignant glioma.

@en

prefLabel

Phase 1 trial of irinotecan pl ...... or recurrent malignant glioma.

@ast

Phase 1 trial of irinotecan pl ...... or recurrent malignant glioma.

@en

P1433

Q35800752-1C183EE7-6925-4058-9459-23EB0FBB1CAB

P1476

Q35800752-C2C33124-641C-4AD8-A182-6A5A81095BBF

P2093

Q35800752-1D90A355-E8E0-45D5-8CA0-2FFB94260679

Q35800752-37A55862-2A39-42BA-988D-E2E9E7E9F114

Q35800752-398B559A-3EA0-49E9-AA75-6ABEDF10EF0C

Q35800752-3E02B8C0-B2ED-4D9B-A28A-5FDBCE9E0EA9

Q35800752-48AEB9F9-2BEF-46D5-BBC6-26BD823A2C78

Q35800752-5A4A4011-9954-408B-819F-49C7D90CD6C2

Q35800752-5B3BC5D4-F8E3-45E3-A85C-6115232232BF

Q35800752-7306CE01-B1C4-4BC8-8C70-4CC8FD486372

Q35800752-7898208A-1FBD-455A-90F6-75C8FC3996CA

Q35800752-7F1FFDAA-07BC-4D47-9BF0-0E57F69CF2A0

P2860

Q35800752-15C054C6-C7A1-4F94-BAE4-267B30F4D3AA

Q35800752-38253DD6-F4D8-4649-B8E1-EC163F137C1E

Q35800752-3FEE45BB-990A-4F27-97FB-E5C69FCBA422

Q35800752-43F81F72-735B-46A8-892D-4934D985F3EA

Q35800752-48B9B39C-CE10-49C1-936F-615E8175F9E0

Q35800752-5E3A459E-3C4A-4E02-87EB-93139854447D

Q35800752-9539BEC2-17E3-49C7-9782-3335234778A3

Q35800752-C0044ED0-56B1-4C90-B653-2C98FEC56A65

Q35800752-C1942779-B871-4880-89C1-28324700A9C6

Q35800752-ECE407EF-F633-4913-BBF5-063D42C0CF6D

P304

Q35800752-9019DD6D-6BE5-4A5F-93DF-CD0D7F929ADD

P31

Q35800752-35CE6819-8DCF-4D6C-A51B-258684A2FBEB

P356

Q35800752-F37834A0-765E-42F8-AEFD-D14686CFC284

P433

Q35800752-3ADE68CA-1478-4ED3-8D9D-92EE428B0633

P478

Q35800752-6DBC0588-C0C7-4F82-8148-F05BB9DF7661

P50

Q35800752-6FA4FDA7-5ECB-47F1-B300-C61C17EC6710

Q35800752-951FCCFD-230A-4CCB-9A75-38473E0C76DE

Q35800752-B4DDAD8F-E18B-40D7-ABCB-98C927E300AD

Q35800752-BF4C14FA-98C2-4CAD-A773-869AD21D0EEE

Q35800752-EA01894A-6CC0-41F3-A763-08A6487B836A

P577

Q35800752-AF4D5E82-763C-4FD5-BD5B-0706086417C4

P698

Q35800752-102B2696-5663-4F7C-B8BC-EEB8B3F63729

P921

Q35800752-C60E7CEB-F91C-4A30-BF7E-DD4FD8D25E8F

P932

Q35800752-13492183-F8B0-4B6D-A6D8-CA1E1DB429BE

P356

S1152851703000498

P1433

P1476

Phase 1 trial of irinotecan pl ...... or recurrent malignant glioma.

@en

P2093

Amy Walker

http://www.w3.org/2001/XMLSchema#string

Christy Lentz

http://www.w3.org/2001/XMLSchema#string

Cindy Bohlin

http://www.w3.org/2001/XMLSchema#string

Deborah Allen

http://www.w3.org/2001/XMLSchema#string

Holly Schweitzer

http://www.w3.org/2001/XMLSchema#string

James E Herndon

http://www.w3.org/2001/XMLSchema#string

James M Provenzale

http://www.w3.org/2001/XMLSchema#string

James Vredenburgh

http://www.w3.org/2001/XMLSchema#string

Jennifer A Quinn

http://www.w3.org/2001/XMLSchema#string

Jeremy N Rich

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies

Altered irinotecan metabolism in a patient receiving phenytoin.

Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study.

Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.

Therapy of adult malignant brain tumors: what have the clinical trials taught us?

The basis for current treatment recommendations for malignant gliomas.

The current status of camptothecin analogues as antitumor agents.

Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma.

Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy.

Irinotecan therapy in adults with recurrent or progressive malignant glioma.

P304

145-153

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1215/S1152851703000498

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Darell D. Bigner

Henry Seth Friedman

Sridharan Gururangan

David A Reardon

P577

2004-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15134629

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

1871988

http://www.w3.org/2001/XMLSchema#string